Crescent Biopharma Inc Stock Price, News & Analysis

ShouTi Inc., a clinical-stage biopharmaceutical company, has appointed Sharon Tetlow to its board of directors, where she will also chair the audit committee. With over 30 years of experience in life sciences finance, Tetlow has previously held senior roles including CFO at various biopharmaceutical firms. She currently serves on the boards of Dice Therapeutics (DICE), Valneva SE (VALN), and Catalyst Biosciences (CBIO). Her expertise is expected to strengthen ShouTi's growth strategy as the company focuses on developing innovative oral therapeutics for chronic diseases.

Catalyst Biosciences (NASDAQ: CBIO) has regained full rights to CB 2782-PEG, a C3-degrader aimed at treating dry AMD, after Biogen ended their collaboration. CEO Nassim Usman highlighted the potential of CB 2782-PEG and another candidate, CB 4332, to address a significant market opportunity in dry AMD, estimated over $10 billion. The press release also notes the challenges ahead, including the need for further clinical trials and potential market risks.

Catalyst Biosciences (NASDAQ: CBIO) has engaged Perella Weinberg Partners as a financial advisor to explore strategic alternatives. The collaboration aims to monetize its hemophilia assets and find partners for its complement asset development. CEO Nassim Usman emphasized PWP's extensive network and expertise in accelerating business development efforts. Catalyst focuses on developing innovative protease therapeutics, addressing unmet medical needs in complement system disorders, including their CB 4332 protease and partnerships with Biogen.

Catalyst Biosciences announces the FDA's Rare Pediatric Disease Designation for its product CB 4332, aimed at treating Complement Factor I deficiency.

This designation highlights the unmet medical need in pediatric patients. The CEO, Nassim Usman, expressed commitment to advancing CB 4332 and their complement medicines portfolio. If approved, CB 4332 could qualify for a priority review voucher, a significant benefit under the FDA program.

Catalyst Biosciences announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference scheduled from November 29 to December 2, 2021. Members of the executive team will engage in a fireside chat accessible on-demand starting November 22, 2021, at 10:00 am ET. This event will be available for registered attendees until the conference concludes. The company focuses on protease therapeutics aimed at disorders of the complement system, including its preclinical C3-degrader program licensed to Biogen. An archived webcast will be available for 90 days post-conference.

Catalyst Biosciences (CBIO) reported its Q3 2021 financial results and announced the discontinuation of MarzAA development to focus on complement therapeutics. The decision stems from enrollment challenges and competition in clinical trials. The company plans to seek buyers for its hemophilia assets and anticipates a 40% reduction in burn rate. Financially, Q3 net loss was $25.2 million, compared to $16 million a year prior, with cash reserves of $64.5 million. Catalyst aims to advance its complement program, with notable progress in CB 4332 and ongoing trials.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced that Dr. Grant Blouse will present at two scientific conferences from October 26-30, 2021. The presentations will focus on the ProTUNE™ platform, engineered for potency and specificity in complement-mediated disorders. Dr. Blouse expressed excitement about ProTUNE™ and its C3b/C4b degraders' potential in precision medicine. Catalyst's pipeline includes CB 4332, an enhanced complement factor I protease expected to enter clinical trials in 2022, alongside late-stage programs for treating rare bleeding disorders.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced the resignation of its CFO, Clinton Musil, effective October 29, 2021, for personal reasons. Seline Miller, the controller, is elevated to interim CFO and principal accounting officer while a successor is sought. The CEO, Nassim Usman, expressed gratitude for Musil's contributions as the company advances in its Protease Medicines platform. Catalyst is focused on rare disorders with late-stage programs like MarzAA and preclinical candidates targeting rare diseases.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced that the U.S. FDA has granted Orphan Drug Designation for its candidate, Marzeptacog alfa (MarzAA), aimed at treating Factor VII Deficiency (FVIID). This is the second ODD for MarzAA, which also holds Fast Track Designation for treating Hemophilia A/B with inhibitors and FVIID. The Orphan Drug Designation supports drug development for rare diseases, providing tax credits and marketing exclusivity. Catalyst focuses on rare disorders of the coagulation and complement systems, with MarzAA being a key part of its late-stage clinical programs.